Lexeo Therapeutics: Behind The Rebound

Core Insights - Lexeo Therapeutics, Inc. (LXEO) shares have tripled since a financing round in May 2025, driven by FDA alignment on a registrational trial for its LX2006 therapy [1] Company Overview - Lexeo Therapeutics is focused on gene therapy and has seen significant stock price appreciation due to positive regulatory developments [1] Market Commentary - The Biotech Forum, led by Bret Jensen, provides insights into high beta biotech stocks and offers a model portfolio of 12-20 stocks with high upside potential [1]